Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.48 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6996421 | 1.00 | PARP1 (0.48) | PARP1SMYD3PDE3BPDE3AALOX5 | |
| SCHEMBL6992815 | 0.90 | PARP1 (0.48) | PARP1SMYD3PDE3BPDE3AALOX5 | |
| SCHEMBL6992811 | 0.90 | PARP1 (0.48) | PARP1SMYD3PDE3BPDE3AALOX5 | |
| SCHEMBL531954 | 0.88 | ALOX5 (0.55) | PARP1SMYD3PDE3BPDE3AALOX5 | |
| SCHEMBL531955 | 0.88 | ALOX5 (0.55) | PARP1SMYD3PDE3BPDE3AALOX5 | |
| SCHEMBL8119255 | 0.87 | PARP1 (0.43) | PARP1SMYD3PDE3BPDE3AALOX5 | |
| SCHEMBL6992674 | 0.86 | ALOX5 (0.41) | PARP1SMYD3ALOX5 | |
| SCHEMBL10222486 | 0.82 | ALOX5 (0.62) | PARP1SMYD3ALOX5USP2GAA | |
| SCHEMBL6998657 | 0.80 | PARP1 (0.59) | PARP1SMYD3PDE3BPDE3AALOX5 | |
| SCHEMBL5342897 | 0.79 | PARP1 (0.57) | PARP1SMYD3PDE3BPDE3AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1015437-B1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS | SCHERING AG (DE) | 2003-12-03 | — | — | EP | disclosed |
| US-6365736-B1 | TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | disclosed |
| EP-1015437-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999012915-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-03-18 | — | — | WO | disclosed |